✦ LIBER ✦

PND3 Risk-Benefit Analysis of Therapy in Multiple Sclerosis

✍ Scribed by N. Qizilbash; I. Méndez; R. Sánchez-de la Rosa

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PND1 A Risk-Benefit Analysis of Natalizu

✍ A.R. Walker; B. Deniz; S.T. Alexopoulos; R. Arnold; D. Bates 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PND24 Cost of Symptomatic Drug Therapy i

✍ E. Fogarty; L. Tilson; M. Barry 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Cyclophosphamide as second-line therapy

✍ Luciano Rinaldi; P. Perini; M. Calabrese; P. Gallo 📂 Article 📅 2009 🏛 Springer Milan 🌐 English ⚖ 137 KB

PND3 EFFICACY AND TOLERABILITY OF NATALI

✍ S Nikfar; R Rahimi; A Rezaie; M Abdollahi 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

PND1 ASSESSING THE NET CLINICAL BENEFIT

✍ A AL-Sabbagh; R Bennett; R Glanzman 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

PND12 The Costs Analysis of Multiple Scl

✍ H. Khanizadeh; M. Izham; A. Akmal 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB